Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tenofovir Disoproxil Treated HBV with Fewer Future HCCs

Publish date:: April 26, 2019

Key clinical point: Two first-line treatments for chronic hepatitis B virus may differ in their ability to prevent hepatocellular carcinoma.

Major finding: In a propensity score-adjusted analysis, treatment with tenofovir disoproxil linked with a 64% reduced incidence of hepatocellular carcinoma.

Study details: Review of 29,350 Hong Kong residents treated for chronic hepatitis B infection during 2010-2018.

Disclosures: Dr. Wong has been an adviser to Gilead, and has been a speaker on behalf of Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead, Janssen, and Roche. Tenofovir disoproxil fumarate (Viread) is marketed by Gilead, and entecavir (Baraclude) is marketed by Bristol-Myers Squibb.

Citation:

Wong GL et al. J Hepatol. 2019 April;70[1]:e128.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,